Wobble Genomics Ltd

🎥 Investment Manager, Lee Lindley explains a little more about why Mercia Ventures led a £8.5million fundraise into Wobble Genomics Ltd, and details how its groundbreaking technology could be transformational in helping to change people's outcomes. Full video link in comments ⏬ #VCT #WhyWeInvested #Genomics #RNA #Investment #VentureCapital

Wobble Genomics Ltd has emerged from stealth mode, revealing revolutionary early detection technology for breast cancer.🧬 At a recent conference in San Francisco, Wobble Genomics showcased their cutting-edge technology that detects rare RNA transcript variants missed by other methods. In March, we proudly led a £8.5 million funding round in Edinburgh-based Wobble Genomics as part of our early-stage offering. To find out more about Wobble's technology, read the full press release here: https://lnkd.in/eyfTRmjs #CancerDetection #LifeSciences #Genomics #Investment #Technology

🔬 In March of this year, Mercia Ventures led a £8.5million fundraise into Edinburgh-based Wobble Genomics Ltd. Wobble has found a way to detect previously invisible ‘full length’ RNA, and the technology could have wide-ranging applications, from drug development and research to agriculture and ecology. CEO and Founder Dr Richard Kuo explains more about this technology that will have a massive impact on the future of health care, biosecurity and biodiversity. Full video link in comments ⏬ #VCT #Edinburgh #Genomics #RNA #BioTech #Investment #VentureCapital

Excited to unveil the groundbreaking work Wobble Genomics Ltd is doing now that we've emerged from stealth mode: we are now able to see cancer in a way that has never been seen before. Today at the Early Detection of Cancer Conference (EDCC) in San Francisco, we're presenting our innovative diagnostics platform using long read RNA sequencing. From our prospective breast cancer clinical study, we've demonstrated ability to detect rare full-length RNA transcript variants not picked up by other methods. By leveraging these full-length transcripts as biomarkers, we achieved 80% sensitivity and 95% specificity in early-stage breast cancer detection. This breakthrough enables us to distinguish cancer-associated RNA sequences from controls and discover new, unique transcripts, paving the way for a strong predictive diagnostic for early-stage breast cancer—arguably one of the most challenging cancers to diagnose via liquid biopsy. Read our full press release for more detail: https://lnkd.in/deKsv3WH If you're attending EDCC and want to learn more about our results, join our Founder and CEO, Dr. Richard Kuo and Chief Medical Officer, Dr. Richard Hockett at the poster session today at from 15:10-15:55. A huge thank you to the entire Wobble Genomics Ltd for their work in achieving these milestones. And special thanks to the team at M+F Health (Anna Hollaway, Claudia Bolouri, Kirsty Clark, Jonathan Baily & Georgia Bron) for their exceptional support during our emergence from stealth mode. There are more exciting developments ahead! 👀 #EdxConf24

We’re thrilled to announce that Wobble Genomics has officially emerged from stealth mode 🚀 To introduce ourselves, we are a pioneering healthcare and biotechnology company at the forefront of long-read RNA sequencing. Today, at the Early Detection of Cancer Conference 2024, the team will present data demonstrating that our technology can detect rare full-length RNA transcript variants not picked up by other methods. We look forward to collaborating with leading academics and researchers across the world to ultimately improve patient care. Read the full press release here: https://lnkd.in/deKsv3WH #EdxConf24

After a period of focused innovation, we can’t wait to share what we’ve been working on – stay tuned as we prepare to emerge from stealth mode 👀 We’re looking forward to presenting our findings tomorrow at Early Detection of Cancer Conference 2024 🧬 #EdxConf24